NO_LONGER_AVAILABLENot Applicable

Managed Access Program for Momelotinib in Myelofibrosis

Plain-language summary

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent can be obtained from the patient or legally authorised representative as per local regulations * Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia * 18 years or older (at the time consent is obtained) * The patient is willing to abide by the contraception requirements. * No known hypersensitivity to momelotinib, its metabolites, or any of the formulation excipients Exclusion Criteria: * Pregnant or breastfeeding female

Trial details

NCT IDNCT05582083

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Myelofibrosis trials